Eli Lilly Stock a Buy After FDA Signs Off on New Weight-Loss Drug? Hosted by MarketBeat StaffNovember 28, 2023 ShareLink copied to clipboard. Play video for Eli Lilly Stock a Buy After FDA Signs Off on New Weight-Loss Drug?DetailsGuestsIn this video, we dive into the evolving pharmaceutical landscape with Dylan Jovine from Behind the Markets. We unpack the explosive growth expected in the weight loss drug industry, projected to hit a whopping $150-200 billion by 2030. There are major players strategically positioning themselves in this market, and we'll uncover the intense competition between giants like Novo Nordisk and Eli Lilly, fighting for dominance with their groundbreaking weight loss drugs. Plus, discover the potential impact on stock values and the healthcare industry as a whole. We'll also discuss the critical phase transitions in FDA drug approval, spotting opportunities, and why investing in biotech has Dylan so bullish on its future.Read Ozempic vs. Mounjaro:: Battle of the bulgeStocks Mentioned in This EpisodeCompanyMarketRank™Current PriceDividend YieldP/E RatioLLYEli Lilly and Company4.9951 of 5 stars$778.30-0.1%0.77%84.14NVONovo Nordisk A/S3.876 of 5 stars$108.030.0%0.67%34.96 Compare These Stocks Add These Stocks to My Watchlist Laycee Kluin, HostDigital Marketing Strategist, MarketBeatAs MarketBeat's Digital Marketing Strategist, Laycee helps with the marketing side of tasks including developing email campaigns, running the promotion of the MarketBeat products and exploring social media opportunities. She felt called to the Marketing industry because she enjoys collaborating with people and making connections. The University of Sioux Falls alum majored in Media Studies with minors in Communications and Spanish. Laycee brings a background in Financial Services Marketing.Previous VideoAll VideosNext Video Subscribe on YouTube Don't Miss a Video Subscribe to watch the latest stock market videos from MarketBeat. We empower investors to make better trading decisions by providing real-time financial data and objective market analysis. Subscribe on YouTube More From MarketBeatAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | Sponsored7 Russell 2000 Stocks to Buy as Sector Rotation BeginsThe myth of the Russell 2000 index is that it's a small-cap index. In reality, the index focuses on both small...MarketBeatDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored7 Alcohol Stocks Primed to Pour ProfitsIn 2020 and 2021, alcohol stocks were among the best-performing consumer staples stocks. But it's been a diffe...MarketBeat$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored7 Oversold Stocks That Could Be Setting Up for a RallyIn 2024, investors are still wrestling with uncertainty. Will there be rate cuts, and what will they mean for ...MarketBeat Recent Videos Featured Articles and Offers2 Underrated Quantum Computing Companies Starting to RallyDecember 20, 2024View 2 Underrated Quantum Computing Companies Starting to RallyURGENT: This Altcoin Opportunity Won’t Wait – Act NowFrom Crypto Swap Profits(Ad)View URGENT: This Altcoin Opportunity Won’t Wait – Act NowAI’s Next Big Winners: 3 Small-Cap Stocks to Watch in 2025December 19, 2024View AI’s Next Big Winners: 3 Small-Cap Stocks to Watch in 2025Broadcom’s Stellar Outlook Sparks Hopes for a Semi Sector RallyDecember 17, 2024View Broadcom’s Stellar Outlook Sparks Hopes for a Semi Sector RallyMicron Stock Under $100: Seize the AI-Driven UpsideDecember 19, 2024View Micron Stock Under $100: Seize the AI-Driven UpsideURGENT: This Altcoin Opportunity Won’t Wait – Act NowFrom Crypto Swap Profits(Ad)View URGENT: This Altcoin Opportunity Won’t Wait – Act Now Search Headlines Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Hosted by MarketBeat StaffNovember 28, 2023 ShareLink copied to clipboard. Play video for Eli Lilly Stock a Buy After FDA Signs Off on New Weight-Loss Drug?DetailsGuestsIn this video, we dive into the evolving pharmaceutical landscape with Dylan Jovine from Behind the Markets. We unpack the explosive growth expected in the weight loss drug industry, projected to hit a whopping $150-200 billion by 2030. There are major players strategically positioning themselves in this market, and we'll uncover the intense competition between giants like Novo Nordisk and Eli Lilly, fighting for dominance with their groundbreaking weight loss drugs. Plus, discover the potential impact on stock values and the healthcare industry as a whole. We'll also discuss the critical phase transitions in FDA drug approval, spotting opportunities, and why investing in biotech has Dylan so bullish on its future.Read Ozempic vs. Mounjaro:: Battle of the bulgeStocks Mentioned in This EpisodeCompanyMarketRank™Current PriceDividend YieldP/E RatioLLYEli Lilly and Company4.9951 of 5 stars$778.30-0.1%0.77%84.14NVONovo Nordisk A/S3.876 of 5 stars$108.030.0%0.67%34.96 Compare These Stocks Add These Stocks to My Watchlist Laycee Kluin, HostDigital Marketing Strategist, MarketBeatAs MarketBeat's Digital Marketing Strategist, Laycee helps with the marketing side of tasks including developing email campaigns, running the promotion of the MarketBeat products and exploring social media opportunities. She felt called to the Marketing industry because she enjoys collaborating with people and making connections. The University of Sioux Falls alum majored in Media Studies with minors in Communications and Spanish. Laycee brings a background in Financial Services Marketing.Previous VideoAll VideosNext Video Subscribe on YouTube Don't Miss a Video Subscribe to watch the latest stock market videos from MarketBeat. We empower investors to make better trading decisions by providing real-time financial data and objective market analysis. Subscribe on YouTube More From MarketBeatAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | Sponsored7 Russell 2000 Stocks to Buy as Sector Rotation BeginsThe myth of the Russell 2000 index is that it's a small-cap index. In reality, the index focuses on both small...MarketBeatDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored7 Alcohol Stocks Primed to Pour ProfitsIn 2020 and 2021, alcohol stocks were among the best-performing consumer staples stocks. But it's been a diffe...MarketBeat$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored7 Oversold Stocks That Could Be Setting Up for a RallyIn 2024, investors are still wrestling with uncertainty. Will there be rate cuts, and what will they mean for ...MarketBeat
